Mazdutide Research Peptide (RUO)

What is Mazdutide?

Mazdutide is a long-acting dual agonist of the GLP-1 (glucagon-like peptide-1) receptor and the glucagon receptor (GCGR). It is a synthetic 34-amino-acid analogue of the gut hormone oxyntomodulin, modified for extended half-life: an Aib (2-aminoisobutyric acid) substitution at position 2 confers resistance to DPP-4 degradation, and acylation with a C20 (eicosanedioic) fatty di-acid attached to lysine 20 through an AEEA-AEEA-γGlu linker drives strong albumin binding and an extended half-life. By engaging both incretin and glucagon pathways, the molecule is studied in obesity and type 2 diabetes research.

Mazdutide (CAS 2259884-03-0, molecular formula C210H322N46O67, ~4563.14 g/mol) is a lyophilised peptide. Its regulatory status varies by region: it has been approved by China's NMPA for chronic weight management and for glycaemic control in type 2 diabetes, while outside China it remains investigational and in late-stage clinical development. It is not yet approved by the US FDA or EMA.

How Mazdutide Is Produced & Characterised

Mazdutide is a synthetically demanding acylated peptide: the 34-mer oxyntomodulin backbone, the non-proteinogenic Aib residue and the lipid side-chain conjugation all create opportunities for deletion sequences, diastereomers and incomplete acylation. As an industry reference point, peptides of this class are typically prepared by optimised Fmoc solid-phase peptide synthesis (SPPS) with controlled side-chain conjugation, then purified on preparative dynamic axial compression (DAC) HPLC columns to resolve the target sequence from closely related impurities.

Production campaigns for this peptide class generally progress from optimisation runs through kilogram and multi-kilogram scale, finished by lyophilisation to a stable, uniform powder. Repeatable batch-to-batch consistency depends on process development, technology transfer and scale-up controls, which is why molecules such as mazdutide are commonly advanced from clinical to commercial scale through specialist contract development and production routes.

Regulatory Context & Handling Reference

The regulatory pathway for mazdutide differs by jurisdiction. It has been approved as an active ingredient by China's NMPA, for chronic weight management and for glycaemic control in type 2 diabetes (both 2025), while outside China it remains investigational and in late-stage clinical development, and is not yet approved by the US FDA or EMA. Where a peptide active ingredient is filed for regulated use, dossiers such as a US-DMF Type II and CTD Module 3 CMC sections, ICH Q2(R1) analytical validation packages and stability data are the standard supporting documentation referenced by finished-product submissions (IND/NDA/ANDA where applicable).

Research supply from Winhycare Pharma

Winhycare Pharma supplies research-grade Mazdutide to research organisations and individual researchers for research and development purposes. Material is supplied at high purity (>99%) under stringent quality control with QC documentation, in secure packaging through global standard logistics, with dedicated technical assistance from our team. We focus on consistent quality and purity, reliable and timely supply, confidential and professional service, and long-term partnerships.

Research use only. Not for human or veterinary use, and not for use in food, drugs, medical devices or cosmetics.

To enquire, tell us the quantity you need, the purity grade, the documentation you require and the destination country. The buyer is responsible for complying with the import and use regulations that apply to Mazdutide in their country.